digital therapeutics

By Dave Muoio January 24, 2019
The acceptability, safety, feasibility and preliminary efficacy of Meru Health’s digital therapeutic for depression will be evaluated in a new two-year investigation conducted by Stanford Medicine and VA Palo Alto Health Care System researchers. According to a clinicaltrials.gov listing, the research program will enroll older adults aged at least 40 years with depressive symptoms in two studies...
By Dave Muoio January 17, 2019
In conjunction with Fairview Health Services and University of Minnesota Health, Proteus Digital Health unveiled plans to pair its sensor-equipped digital pills with an oral oncology therapeutic. According to an announcement from Proteus, the new care model is currently being used to treat stage 3 and stage 4 colorectal cancer patients receiving care at Fairview. There, clinicians are prescribing...

Left to right: Dr. Daniel Kraft, Fitbit's Any McDonough, Verily's Dr. Jess Mega and Akili's Eddie Martucci chat on stage at CES 2019’s Digital Health Summit

By Dave Muoio January 9, 2019
Digital therapeutics are a nascent corner of the healthcare technology industry. With few precedents available outside of novel drugs or medical devices, it would make sense that Pear Therapeutics, Proteus and other digital therapeutics companies furthest along the regulatory pipeline align themselves with industry partners well versed in selling and supporting a medical product. As such, it came...
By Dave Muoio January 3, 2019
A small feasibility study conducted by the Children’s Hospital of Philadelphia suggests that Project: Evo, the digital medicine developed by Akili Interactive Labs that is delivered via a video game, continually engaged children with autism spectrum disorder (ASD) and reduced their ADHD symptoms, although more objective measures of cognitive control were mixed. Topline data Nineteen children aged...
By Laura Lovett January 3, 2019
This morning Otsuka America, a subsidiary of the Japanese pharma company, announced that it is teaming up with Click Therapeutics, maker of software as a prescription medical treatment, to create a new digital therapeutic to treat major depressive disorder (MDD).  The goal of the partnership is to develop a software app that will employ cognitive therapy principles and can be used either with or...
By Dave Muoio November 20, 2018
reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April. But while physical prescription drugs are usually handled through a pharmacy, the process...

The digital health landscape, from the Digital Therapeutics Alliance's new report.

By Jonah Comstock October 31, 2018
The precise definition of digital therapeutics has been a hot topic as the new technology category has been discussed and debated in event sessions and articles over the last few years. Now the Digital Therapeutics Alliance, a consortium of industry stakeholders, is hoping to put that to rest with an official definition, released this week in a whitepaper. The definition reads as follows:   "...
By Dave Muoio October 15, 2018
Proteus Digital Health and Otsuka Pharmaceutical have expanded their partnership on digital therapeutics. On Thursday, Proteus announced that it received $88 million from the pharma company, which will go toward the continued development and commercialization of its ingestible sensor pill platform. Additionally, the five-year deal will also support the investigation of a wider digital medicine...
By Jonah Comstock October 15, 2018
As digital therapeutics move to cross boundaries of regulatory approval and efficacy data, the healthcare industry will begin to move to a bifurcated world of digital health apps in the same way that drugs are now divided up into largely unregulated supplements and heavily regulated pharmaceuticals. At the Digital Health Innovation Summit last week in Boston, Sanofi Ventures Senior Director of...
By Dave Muoio September 12, 2018
Digital therapeutics maker Akili Interactive Labs today announced a deal with the University of California’s governing board concerning exclusive licensing of a new technology that will combine the company’s focus on neural systems with physical activity. Developed at the Neuroscape Lab at UCSF, the tech follows in the footsteps of Akili’s other efforts in that it is primarily delivered through a...